+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Advanced Therapy Medicinal Products CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F- Product Image
Advanced Therapy Medicinal Products CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F- Product Image
New

Advanced Therapy Medicinal Products CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • PDF Icon

    Report

  • 180 Pages
  • February 2025
  • Region: Global
  • TechSci Research
  • ID: 5908279
Free Webex Call
10% Free customization
Description Jump to:
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

 10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The Advanced Therapy Medicinal Products CDMO Market was valued at USD 5.12 Billion in 2024, and is expected to reach USD 8.87 Billion by 2030, rising at a CAGR of 9.54%. The Global Advanced Therapy Medicinal Products CDMO Market is a dynamic and rapidly evolving sector within the pharmaceutical and biotechnology industries. This market encompasses organizations that provide specialized services for the development and manufacturing of advanced therapy medicinal products (ATMPs), which include gene therapies, cell therapies, and tissue-engineered products.

Key Market Drivers

Proliferation of Advanced Therapies

The healthcare landscape is witnessing a revolution as advanced therapies, including gene therapies, cell therapies, and tissue-engineered products, emerge as groundbreaking treatments for previously incurable diseases. This paradigm shift in medicine is driving the demand for specialized services provided by Contract Development and Manufacturing Organizations (CDMOs).

The advent of advanced therapies has expanded therapeutic horizons, offering new hope to patients suffering from rare and debilitating conditions. These therapies target the root causes of diseases at the genetic and cellular levels, promising higher efficacy and fewer side effects compared to traditional treatments. As more conditions become treatable through advanced therapies, the demand for CDMO services to develop and manufacture these products increases.

Pharmaceutical companies, biotechnology firms, and academic institutions are investing heavily in advanced therapy research and development. This surge in investment translates into a growing pipeline of potential therapies. CDMOs are integral to this process, providing the expertise and infrastructure needed to advance these therapies from the laboratory to clinical trials and eventual commercialization.

The development and manufacturing of advanced therapies come with complex regulatory challenges. Regulatory bodies like the FDA and EMA have stringent requirements to ensure the safety and efficacy of these novel treatments. CDMOs specializing in advanced therapies possess the regulatory expertise to help clients navigate this intricate landscape, ensuring compliance throughout the product lifecycle. This support streamlines the regulatory approval process, accelerating market entry.

Key Market Challenges

High Costs

The development and manufacturing of advanced therapies, such as ATMPs (Advanced Therapy Medicinal Products), are inherently resource-intensive. These therapies require significant investment in research and development, with cutting-edge technology and highly specialized expertise necessary for their creation. The costs associated with preclinical and clinical trials, regulatory approvals, and the production of these therapies can often be prohibitively high, which poses a challenge for Contract Development and Manufacturing Organizations (CDMOs) involved in the production process.

Furthermore, the advanced nature of these products demands high-quality standards, specialized facilities, and skilled personnel to ensure safety, efficacy, and compliance with stringent regulations. CDMOs must find innovative ways to streamline production processes, optimize resource allocation, and implement cost-control strategies without compromising the quality of the therapies being developed. Balancing cost efficiency while meeting the demands for high-end manufacturing processes is a critical challenge in the ATMP sector, and finding sustainable solutions is key to ensuring the long-term success of these products.

Key Market Trends

Increased Collaboration and Partnerships

Collaboration is increasingly becoming a critical driver of innovation within the Advanced Therapy Medicinal Product (ATMP) sector. As the complexity and scope of these therapies continue to grow, Contract Development and Manufacturing Organizations (CDMOs) are recognizing the importance of strategic partnerships with pharmaceutical companies, biotech startups, and academic institutions.

These alliances allow stakeholders to pool resources, share knowledge, and co-develop cutting-edge therapies that may otherwise be challenging to create independently. In February 2022, Recipharm AB successfully finalized its acquisition of Vibalogics. Through this arrangement, Recipharm is set to gain valuable expertise in biologics, harnessing Vibalogics' capabilities in areas such as viral vaccines, oncolytic viruses, and gene treatments using viral vectors. This strategic move is expected to provide Recipharm with a substantial diversification of its offerings across various technologies and modalities.

Key Market Players

  • Celonic AG
  • Rentschler Biopharma SE
  • Catalent, Inc.
  • Lonza Group AG
  • WuXi Advanced Therapies
  • Minaris Regenerative Medicine, LLC
  • Pluri Biotech Ltd.
  • REPROCELL USA Inc.
  • BioPhorum Operations Group
  • Cellares Corporation

Report Scope:

In this report, the Global Advanced Therapy Medicinal Products CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Advanced Therapy Medicinal Products CDMO Market, By Product:

  • Gene Therapy
  • Cell Therapy
  • Tissue Engineered
  • Others

Advanced Therapy Medicinal Products CDMO Market, By Phase:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Advanced Therapy Medicinal Products CDMO Market, By Indication:

  • Oncology
  • Cardiology
  • Central Nervous System
  • Musculoskeletal
  • Infectious disease
  • Immunology & inflammation
  • Others

Advanced Therapy Medicinal Products CDMO Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Advanced Therapy Medicinal Products CDMO Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Advanced Therapy Medicinal Products CDMO Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Gene Therapy, Cell Therapy, Tissue Engineered, Others)
5.2.2. By Phase (Phase I, Phase II, Phase III, Phase IV)
5.2.3. By Indication (Oncology, Cardiology, Central Nervous System, Musculoskeletal, Infectious disease, Immunology & inflammation, Others),
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Advanced Therapy Medicinal Products CDMO Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Phase
6.2.3. By Indication
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Advanced Therapy Medicinal Products CDMO Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Phase
6.3.1.2.3. By Indication
6.3.2. Canada Advanced Therapy Medicinal Products CDMO Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Phase
6.3.2.2.3. By Indication
6.3.3. Mexico Advanced Therapy Medicinal Products CDMO Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Phase
6.3.3.2.3. By Indication
7. Europe Advanced Therapy Medicinal Products CDMO Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Phase
7.2.3. By Indication
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Advanced Therapy Medicinal Products CDMO Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Phase
7.3.1.2.3. By Indication
7.3.2. United Kingdom Advanced Therapy Medicinal Products CDMO Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Phase
7.3.2.2.3. By Indication
7.3.3. Italy Advanced Therapy Medicinal Products CDMO Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Phase
7.3.3.2.3. By Indication
7.3.4. France Advanced Therapy Medicinal Products CDMO Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Phase
7.3.4.2.3. By Indication
7.3.5. Spain Advanced Therapy Medicinal Products CDMO Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Phase
7.3.5.2.3. By Indication
8. Asia-Pacific Advanced Therapy Medicinal Products CDMO Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Phase
8.2.3. By Indication
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Advanced Therapy Medicinal Products CDMO Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Phase
8.3.1.2.3. By Indication
8.3.2. India Advanced Therapy Medicinal Products CDMO Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Phase
8.3.2.2.3. By Indication
8.3.3. Japan Advanced Therapy Medicinal Products CDMO Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Phase
8.3.3.2.3. By Indication
8.3.4. South Korea Advanced Therapy Medicinal Products CDMO Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Phase
8.3.4.2.3. By Indication
8.3.5. Australia Advanced Therapy Medicinal Products CDMO Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Phase
8.3.5.2.3. By Indication
9. South America Advanced Therapy Medicinal Products CDMO Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Phase
9.2.3. By Indication
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Advanced Therapy Medicinal Products CDMO Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Phase
9.3.1.2.3. By Indication
9.3.2. Argentina Advanced Therapy Medicinal Products CDMO Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Phase
9.3.2.2.3. By Indication
9.3.3. Colombia Advanced Therapy Medicinal Products CDMO Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Phase
9.3.3.2.3. By Indication
10. Middle East and Africa Advanced Therapy Medicinal Products CDMO Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Phase
10.2.3. By Indication
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Advanced Therapy Medicinal Products CDMO Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Phase
10.3.1.2.3. By Indication
10.3.2. Saudi Arabia Advanced Therapy Medicinal Products CDMO Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Phase
10.3.2.2.3. By Indication
10.3.3. UAE Advanced Therapy Medicinal Products CDMO Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Phase
10.3.3.2.3. By Indication
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Porter’s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. Competitive Landscape
14.1. Celonic AG
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Financials (As Reported)
14.1.5. Recent Developments
14.1.6. Key Personnel Details
14.1.7. SWOT Analysis
14.2. Rentschler Biopharma SE
14.3. Catalent, Inc.
14.4. Lonza Group AG
14.5. WuXi Advanced Therapies
14.6. Minaris Regenerative Medicine, LLC
14.7. Pluri Biotech Ltd.
14.8. REPROCELL USA Inc.
14.9. BioPhorum Operations Group
14.10. Cellares Corporation
15. Strategic Recommendations16. About the Publisher & Disclaimer

Companies Mentioned

  • Celonic AG
  • Rentschler Biopharma SE
  • Catalent, Inc.
  • Lonza Group AG
  • WuXi Advanced Therapies
  • Minaris Regenerative Medicine, LLC
  • Pluri Biotech Ltd.
  • REPROCELL USA Inc.
  • BioPhorum Operations Group
  • Cellares Corporation

Table Information

Report AttributeDetails
No. of Pages180
PublishedFebruary 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 5.12 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.87 Billion
Compound Annual Growth Rate9.5%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Advanced Therapy Medicinal Products CDMO Market by Products, Phase, Indication, End-Users - Global Forecast 2025-2030 - Product Image

Advanced Therapy Medicinal Products CDMO Market by Products, Phase, Indication, End-Users - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Advanced Therapy Medicinal Products Contract Development and Manufacturing Organization (CDMO) Global Market Report 2024 - Product Image

Advanced Therapy Medicinal Products Contract Development and Manufacturing Organization (CDMO) Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Global Market Report 2024 - Product Image

Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Cell & Gene Therapy Biomanufacturing CDMO Market by Component, Phase, Indication - Global Forecast 2025-2030 - Product Image

Cell & Gene Therapy Biomanufacturing CDMO Market by Component, Phase, Indication - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Advanced Therapy Medicinal Products Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Advanced Therapy Medicinal Products Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.